钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂用于成人慢性肾脏病:一项临床实践指南
该指南针对成人慢性肾脏病(CKD)患者,基于13项试验共29614名参与者的系统综述与Meta分析证据,按CKD进展和并发症风险分层给出推荐:低、中风险者建议使用SGLT-2抑制剂(弱推荐),高、极高风险者推荐使用(强推荐),适用人群不论是否合并2型糖尿病。
要点
- 低风险成人:建议使用SGLT-2抑制剂(弱推荐)。
- 中风险成人:建议使用SGLT-2抑制剂(弱推荐)。
- 高风险和极高风险成人:推荐使用SGLT-2抑制剂(强推荐)。
核心结论
- 指南推荐对CKD进展和并发症高风险及极高风险的成人使用SGLT-2抑制剂(强推荐),对低风险和中风险成人建议使用(弱推荐),适用于所有CKD成人,不论2型糖尿病状态。
研究设计与样本
- 国际专家组(包括患者、临床医生和方法学家)按照可信指南标准并采用GRADE方法制定本指南。
- 专家组使用KDIGO分类系统确定CKD成人从低到极高的典型风险分层,并以患者个体视角从证据过渡到推荐。
- 证据来源于一项关联的系统综述与配对Meta分析,纳入13项试验共29614名参与者,评估SGLT-2抑制剂在伴或不伴2型糖尿病的CKD成人中的获益与危害。
主要发现
- 在CKD进展和并发症极高风险个体中,中至高确定性证据表明SGLT-2抑制剂(相对于安慰剂或不含SGLT-2抑制剂的标准治疗)降低全因死亡、心血管死亡、心力衰竭住院、肾衰竭、非致死性心肌梗死和非致死性卒中。
- 在高风险个体中,中至高确定性证据表明SGLT-2抑制剂在多数结局上显示相似获益,但对心力衰竭住院和肾衰竭显示很小或无效果。
- 在中风险和低风险个体中,中至高确定性证据表明SGLT-2抑制剂可能降低全因死亡和非致死性卒中,对其他获益结局显示很小或无效果。
- 危害结局缺乏风险分层估计,专家组因此考虑跨风险分层汇总的绝对效应;SGLT-2抑制剂对需要透析的急性肾损伤、骨折、下肢截肢、酮症酸中毒、生殖器感染或症状性低血容量显示很小或无影响,但个体患者层面仍存在残余危害可能性。
关键数值与推荐
- 低风险CKD进展和并发症成人:建议使用SGLT-2抑制剂(弱推荐,支持)。
- 中风险CKD进展和并发症成人:建议使用SGLT-2抑制剂(弱推荐,支持)。
- 高风险CKD进展和并发症成人:推荐使用SGLT-2抑制剂(强推荐,支持)。
- 极高风险CKD进展和并发症成人:推荐使用SGLT-2抑制剂(强推荐,支持)。
临床怎么用
- 应用推荐时,临床医生须适当识别CKD成人,考虑潜在病因,并基于肾小球滤过率(估算或实测)和白蛋白尿程度进行风险分层。
- 除风险分层外,可能需根据肾脏疾病程度和其他合并症进一步估计个体风险,以指导个体化决策和共享决策。
- 现有风险计算器可帮助估计个体CKD进展和并发症风险。
局限性
- 危害结局缺乏风险分层估计,专家组因此考虑跨风险分层汇总的绝对效应。
- SGLT-2抑制剂对需要透析的急性肾损伤、骨折、下肢截肢、酮症酸中毒、生殖器感染或症状性低血容量显示很小或无影响,但个体患者层面仍存在残余危害可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: What is the impact of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on survival and on cardiovascular and kidneyoutcomes for adults living with chronic kidney disease (CKD)? CURRENT PRACTICE: Few therapies slow kidney disease progression and improve long term prognosis for adults living with CKD. SGLT-2 inhibitors have demonstrated cardiovascular and kidney benefits in adults with CKD with and without type 2 diabetes. Existing guidance for SGLT-2 inhibitors does not account for the totality of current best evidence for adults with CKD and does not provide fully stratified treatment effects and recommendations across all risk groups based on risk of CKD progression and complications. RECOMMENDATIONS: The guideline panel considered evidence regarding benefits and harms of SGLT-2 inhibitor therapy for adults with CKD over a five year period, along with contextual factors, and provided the following recommendations:1. For adults at low risk of CKD progression and complications, we suggest administering SGLT-2 inhibitors (weak recommendation in favour)2. For adults at moderate risk of CKD progression and complications, we suggest administering SGLT-2 inhibitors (weak recommendation in favour)3. For adults at high risk of CKD progression and complications, we recommend administering SGLT-2 inhibitors (strong recommendation in favour)4. For adults at very high risk of CKD progression and complications, we recommend administering SGLT-2 inhibitors (strong recommendation in favour).Recommendations are applicable to all adults with CKD, irrespective of type 2 diabetes status. HOW THIS GUIDELINE WAS CREATED: An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified typical risk strata of adults with CKD (from low to very high risk of CKD progression and related complications) using the classification system developed by Kidney Disease Improving Global Outcomes (KDIGO), and applied an individual patient perspective in moving from evidence to recommendations. Effects of SGLT-2 inhibitors were interpreted in absolute terms applicable to different risk strata with varying baseline risks for outcomes of benefit over a five year period. The panel explicitly considered the balance of benefits, harms, and burdens of starting an SGLT-2 inhibitor, incorporating the values and preferences of adults with different risk profiles. Interactive evidence summaries and decision aids accompany multilayered recommendations, developed in an online authoring and publication platform (www.magicapp.org) that allows reuse and adaptation. THE EVIDENCE: A linked systematic review and pairwise meta-analysis (13 trials including 29 614 participants) of benefits and harms associated with SGLT-2 inhibitors in adults with CKD with or without type 2 diabetes informed guidance. Among individuals at very high risk of CKD progression and complications, moderate to high certainty evidence shows SGLT-2 inhibitors (relative to placebo or standard care without SGLT-2 inhibitors) decrease all-cause and cardiovascular mortality, hospitalisation for heart failure, kidney failure, non-fatal myocardial infarction, and non-fatal stroke. Among individuals at high risk, moderate to high certainty evidence shows SGLT-2 inhibitors result in similar benefits across outcomes except demonstrating little or no effect on hospitalisation for heart failure and kidney failure. Among individuals at moderate and low risk, moderate to high certainty evidence shows SGLT-2 inhibitors probably reduce all-cause mortality and non-fatal stroke, with little or no effect for other outcomes of benefit. Risk-stratified estimates were unavailable for outcomes of harm; the panel therefore considered absolute effects summarised across risk strata. SGLT-2 inhibitors are associated with little or no effect on acute kidney injury requiring dialysis, bone fractures, lower limb amputations, ketoacidosis, genital infections, or symptomatic hypovolaemia, although a residual possibility of harms at the individual patient level remains. UNDERSTANDING THE RECOMMENDATION: In order to apply recommendations, clinicians must appropriately identify adults with CKD, consider the underlying aetiology, and risk stratify them based on glomerular filtration rate (estimated or measured) and degree of albuminuria. In addition to classifying individuals into risk strata, further estimation of a given patient's risk based on the extent of their kidney disease and other comorbidities may be warranted to inform individual-level decisions and shared decision making. Available risk calculators may help estimate a given patient's risk of CKD progression and complications.
引用
- Agarwal A, Zeng X, Li S, et al. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline. BMJ. 2024. PMID: 39353639. doi:10.1136/bmj-2024-080257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。